Increased T-cell stimulating activity by mutated SEC2 correlates with its improved antitumour potency

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Recombinant staphylococcal enterotoxins C2 (rSEC2) have shown therapeutic potential.
• Understanding the mechanisms behind improved antitumour activity is crucial for developing novel cancer therapies.

Purpose of the Study:

• To investigate the enhanced antitumour activity of SAM-3 compared to rSEC2.
• To elucidate the immunological mechanisms underlying SAM-3's improved efficacy.

Main Methods:

• In vivo and in vitro assays including methylthiazol tetrazolium, flow cytometry, and quantitative real-time PCR.
• Assessment of T-cell activation, cytokine release, and T-cell receptor (TCR) binding affinity.

Main Results:

• SAM-3 exhibited improved in vivo antitumour activity compared to rSEC2.
• SAM-3 demonstrated enhanced T-cell stimulating potency, leading to massive activation of CD4(+) and CD8(+) T cells and cytokine release.
• Quantitative real-time PCR revealed differences in the quantities of activated T cells bearing specific Vβ, despite similar Vβ specificities induced by SAM-3 and rSEC2.

Conclusions:

• Increased SAM-3-TCR binding affinity is a key factor in its potent T-cell activation and cytokine release.
• SAM-3 significantly amplifies the in vivo antitumour immune response.
• SAM-3 represents a potent therapeutic candidate for clinical tumour treatment.